ABSTRACT
Introduction Men in sub-Saharan Africa are less likely than women to initiate antiretroviral therapy (ART) and are more likely to have longer cycles of disengagement from ART programs. Treatment interventions that meet the unique needs of men are needed, but they must be scalable. We will conduct a study to test the impact of various interventions on six-month retention in ART programs among men living with HIV who are not currently engaged in care.
Methods and Analysis We will conduct a programmatic, individually randomized, non-blinded, non-inferiority controlled trial. “Non-engaged” men will be randomized 1:1:1 to either a Stepped, Low-Intensity, or High-Intensity arm. In the Stepped arm, intervention activities build in intensity over time for those who do not reengage in care with the following steps: 1) one-time male-specific counseling + facility navigation ⟶ 2) ongoing male mentorship + facility navigation ⟶ outside-facility ART initiation + male-specific counseling + facility navigation for follow-up ART visits. The Low-Intensity Intervention includes one-time male-specific counseling + facility navigation only and the High-Intensity Intervention offers immediate outside-facility ART initiation + male-specific counseling + facility navigation for follow-up ART visits. Our primary outcome is 6-month retention in care. Secondary outcomes include cost-effectiveness and rates of adverse events.
Ethics and Dissemination The Institutional Review Board of the University of California, Los Angeles and the National Health Sciences Research Council in Malawi have approved the trial protocol. Findings will be disseminated rapidly in national and international forums, as well as in peer-reviewed journals and are expected to provide urgently needed information to other countries and donors.
Strengths and limitations
IDEAL provides male-specific differentiated models of care aimed to improve men’s ART outcomes. We specifically focus on building trusting relationships with health care workers and developing client-led, individualized strategies to overcome barriers to care.
IDEAL will test the impact of a stepped intervention for men. This approach promises to improve the efficiency and reach of HIV programs for men as the highest-resource interventions will only be received by the minority of men who are most in need.
IDEAL develops and tests male-specific counseling curriculum that, if effective, could easily be taken to scale. Findings from the study will identify critical components for male-specific counseling, especially among men who struggle to be retained in HIV care.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05137210
Funding Statement
The work was supported by the Bill and Melinda Gates Foundation grant number INV-001423. KD was supported by National Institute of Mental Health of the National Institutes of Health grant number R01-MH122308, Fogarty International grant number K01-TW011484-01 and UCLA GSTTP. LL was supported by the National Institute of Mental Health of the National Institutes of Health under grant number K01MH119923. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This protocol manuscript used publicly available and can be found in the reference section. Collection of human subjects data for the trial was approved by the Institutional Review Board of the University of California, Los Angeles and the National Health Sciences Research Council in Malawi. Full findings from the trial will be publicly available upon the trials completion.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail addresses of authors: KD: KDovel{at}mednet.ucla.edu, KB: kelvin{at}pihmalawi.com, JH: jhubbard{at}mednet.ucla.edu, KP: khumbo{at}pihmalawi.com, BN: brooken{at}bu.edu, TC: TCoates{at}mednet.ucla.edu, MK: kulich{at}karlin.mff.cuni.cz, EC: elijah{at}pihmalawi.com, SP: samphiri{at}pihmalawi.com, LL: lclong{at}bu.edu, RH: RHoffman{at}mednet.ucla.edu, AC: augutc{at}gmail.com
Data Availability
All data used to draft this protocol manuscript are publicly available and can be found in the reference section.
